Contineum Therapeutics, Inc. (CTNM)
Develops experimental drug treatments for lung disease, chronic pain, depression, and multiple sclerosis.
$14.16+0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+137.6%
The outlook
CTNM is trading above both its 50- and 200-day moving averages, positioning it in the upper portion of its 52-week range. Analyst coverage shows an average price target about 58% above the current price, though this reflects the wide range of analyst opinions on an early-stage biotech name.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range77% of the way from its 52-week low to high
Price targetAvg target +58% vs current price
Analyst price target
~12-month · 6 analysts$22.33average target+57.7% vs now
Now $14.16
Low $16.00High $28.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$529.4M
52-wk high
$16.91
52-wk low
$5.07
50-day avg
$13.53
200-day avg
$12.84
Trailing P/E
—